Trials / Unknown
UnknownNCT03159052
Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Clinical Trial to Evaluate the Efficacy and Safety of SHR3824 as Monotherapy in in Chinese Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 450 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to obtain information on efficacy and safety of SHR3824 over 24 weeks and 52 weeks in Chinese patients with Type 2 Diabetes. This will be done by comparing the effect of SHR3824 to placebo when given in oral doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR3824 | Once daily, 52 weeks |
| DRUG | Placebo | Once daily, 24 weeks |
Timeline
- Start date
- 2017-06-01
- Primary completion
- 2018-10-01
- Completion
- 2019-06-01
- First posted
- 2017-05-18
- Last updated
- 2017-05-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03159052. Inclusion in this directory is not an endorsement.